Breaking News, Financial News

VitriVax Awarded $9.9M Grant to Scale Up Clinical Manufacturing

The two-year award supports Phase 1-ready GMP manufacturing activities for ALTA technology.

By: Rachel Klemovitch

Assistant Editor

VitriVax, Inc., a vaccine formulation technology company, was awarded a two-year, $9.9 million grant from the Gates Foundation. The funding will support the scale-up of VitriVax’s Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology, enabling Phase 1-ready GMP manufacturing and advancing the platform to prepare for Phase 1 clinical trials. Within the scope of this grant, VitriVax will work with a Contract Development and Manufacturing Organization (CDMO) suited for early-phase ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters